On July 17, Japan’s Cabinet adopted the 2020 Basic Policy on Economic and Fiscal Management and Reform (honebuto). Its initial text suggested the government’s position to carry out its first off-year drug price revision next April as well as its…
HOME > ORGANIZATION
ORGANIZATION
- JPA Supports Ban on “Dispensing Point” Services at Pharmacies
January 26, 2012
- JSMI to Seek Expansions of OTCs by Appealing Preventive Effects in 2012
January 24, 2012
- JPMA to Focus on Thorough Enforcement of Compliance in Next Fiscal Year
January 20, 2012
- JPMA to Discuss State of Long-Listed Products Over a Year Ahead of FY2014 Revision
January 19, 2012
- JPMA to Set Transparency Guideline for Relationships with Patient Organizations, Disclose Information from FY2013
January 19, 2012
- JPWA, NPhA Hold Talks for Distribution Improvement
January 18, 2012
- FPMAJ Detects Radioactive Substances in 2 Crude Raw Material Samples
January 17, 2012
- JGA President Sawai Says Members United to Provide Stable Drug Supplies to Meet Boosted Demand
January 13, 2012
- JPWA President Bessho Expresses Resolve for Distribution Improvement
January 12, 2012
- PMAT President Matsuda Says Permanent Introduction of Premium is Priority Issue
January 10, 2012
- FPMAJ Chairman Pledges Further Efforts for Permanent Introduction of Premium, Caution Towards Additional Price Cuts Becoming Rule
January 5, 2012
- New Year’s Remarks: We wish each of our stakeholders a very Happy and Healthy New Year 2012.
January 5, 2012
- New Year’s Message: On behalf of the JPMA, I would like to express our best wishes for a Happy New Year as we see the start of 2012.
January 5, 2012
- 2012 New Year’s Message: The Ultimate Winner of the Medical Policy Changes is the Patient
January 5, 2012
- JGA to Push for Changing Brand-Based Product Names to Generic Names
December 28, 2011
- JGA President Sawai Says Additional Price Cuts for Generics “In No Way Acceptable”
December 27, 2011
- FPMAJ, JPMA “Truly Regret” Additional Price Cuts for Long-Listed, Generic Drugs
December 27, 2011
- JPMA's Kawabe Says Additional Price Cut for Long-Listed Products is “Not a Rule”
December 22, 2011
- Cancer Patient Groups Submit Petition Asking for Elimination of Drug Lag
December 20, 2011
- Doctor Survey Shows AD at Top of Most Medically Significant Diseases in 2020
December 20, 2011
ページ
Since last year, Japan has seen a number of stock-outs and shortages of generic drugs attributable to API supply disruptions…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…